Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)

Medicare covers the Abbott RealTime IDH1 and IDH2 assays (unmodified Abbott Molecular kits) as aids to identify IDH1 and IDH2 mutations in adult patients with relapsed/refractory acute myeloid leukemia to inform treatment with ivosidenib and enasidenib, respectively, with coverage effective 2017-08-01 for IDH2 and 2018-07-20 for IDH1. Claims must use CPT 81120 (IDH1) or 81121 (IDH2) with 1 unit of service, include the appropriate ICD-10-CM diagnosis code and the DEX Z-Code identifier in the specified claim fields; any laboratory modifications require prior MolDX Technical Assessment before submission.

"Abbott RealTime IDH1 (Abbott Molecular) testing is covered to detect a susceptible IDH1 mutation in adult (>=18) patients with relapsed or refractory acute myeloid leukemia (AML) to identify candid..."

Sign up to see full coverage criteria, indications, and limitations.